Tags

Type your tag names separated by a space and hit enter

Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
J Am Psychiatr Nurses Assoc. 2020 Sep/Oct; 26(5):447-457.JA

Abstract

OBJECTIVE:

This article presents proven, promising, and potential therapeutic uses for cannabidiol (CBD) in the treatment of psychiatric and neurologic conditions and diseases. It presents popular, but scientifically unproven health and therapeutic claims of CBD supporting the beneficial homeostatic effects of the intrinsic or endogenous cannabinoid system. It includes a review of cannabinoid pharmacology; it compares properties and the legal status of CBD and THC (delta 9-tetrahydrocannabinol) as well as the hemp and marijuana varieties of Cannabis, and it reviews the historic 2018 U.S. Food and Drug Administration approval of Epidiolex, an oral solution of cannabidiol for two rare treatment-resistant childhood epilepsies, as the first Cannabis-derived drug.

METHOD:

We reviewed literature on cannabidiol, CBD, the endocannabinoid neuropharmacology system, and hemp and marijuana varieties of Cannabis sativa.

RESULTS:

The proven and promising medical uses and deficiencies of unproven health claims for CBD, legal implications for Cannabis-derived drugs, and comparisons of CBD and THC and hemp and marijuana are summarized objectively with pertinent references.

CONCLUSION:

CBD and CBD and THC combinations have potential to provide safe, effective therapy for several psychiatric and neurologic conditions and diseases. However, such achievement will require a uniform standard of CBD purity and strength, and corroboration from adequately large and rigorously controlled clinical research studies.

Authors+Show Affiliations

Marian Newton, PhD, PMHNP-BC, PMHCNS, ANEF, Eleanor Wade Custer School of Nursing, Shenandoah University, Winchester, VA, USA.David W. Newton, BS Pharm, PhD, FAPhA, Pharmacy Professor Emeritus, Shenandoah University, Winchester, VA, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32508204

Citation

Newton, Marian, and David W. Newton. "Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions." Journal of the American Psychiatric Nurses Association, vol. 26, no. 5, 2020, pp. 447-457.
Newton M, Newton DW. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions. J Am Psychiatr Nurses Assoc. 2020;26(5):447-457.
Newton, M., & Newton, D. W. (2020). Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions. Journal of the American Psychiatric Nurses Association, 26(5), 447-457. https://doi.org/10.1177/1078390320929410
Newton M, Newton DW. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions. J Am Psychiatr Nurses Assoc. 2020 Sep/Oct;26(5):447-457. PubMed PMID: 32508204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions. AU - Newton,Marian, AU - Newton,David W, Y1 - 2020/06/06/ PY - 2020/6/9/pubmed PY - 2021/7/2/medline PY - 2020/6/9/entrez KW - CBD KW - cannabidiol KW - cannabis KW - endocannabinoids KW - hemp SP - 447 EP - 457 JF - Journal of the American Psychiatric Nurses Association JO - J Am Psychiatr Nurses Assoc VL - 26 IS - 5 N2 - OBJECTIVE: This article presents proven, promising, and potential therapeutic uses for cannabidiol (CBD) in the treatment of psychiatric and neurologic conditions and diseases. It presents popular, but scientifically unproven health and therapeutic claims of CBD supporting the beneficial homeostatic effects of the intrinsic or endogenous cannabinoid system. It includes a review of cannabinoid pharmacology; it compares properties and the legal status of CBD and THC (delta 9-tetrahydrocannabinol) as well as the hemp and marijuana varieties of Cannabis, and it reviews the historic 2018 U.S. Food and Drug Administration approval of Epidiolex, an oral solution of cannabidiol for two rare treatment-resistant childhood epilepsies, as the first Cannabis-derived drug. METHOD: We reviewed literature on cannabidiol, CBD, the endocannabinoid neuropharmacology system, and hemp and marijuana varieties of Cannabis sativa. RESULTS: The proven and promising medical uses and deficiencies of unproven health claims for CBD, legal implications for Cannabis-derived drugs, and comparisons of CBD and THC and hemp and marijuana are summarized objectively with pertinent references. CONCLUSION: CBD and CBD and THC combinations have potential to provide safe, effective therapy for several psychiatric and neurologic conditions and diseases. However, such achievement will require a uniform standard of CBD purity and strength, and corroboration from adequately large and rigorously controlled clinical research studies. SN - 1532-5725 UR - https://www.unboundmedicine.com/medline/citation/32508204/Cannabidiol_or_CBD_Oil:_Help_Hope_and_Hype_for_Psychiatric_and_Neurologic_Conditions_ DB - PRIME DP - Unbound Medicine ER -